Meta-regression of trials using carotid intima–media thickness (CIMT) as a surrogate end point leads to unreliable results owing to heterogeneity in methods, interventions, and outcomes of pooled trials. CIMT will continue to be a worthwhile surrogate trial end point supported by two decades of technical progress and clinical atherosclerosis research.
- Allen J. Taylor
- Michiel L. Bots
- John J. P. Kastelein
